ICD Research's Omrix Biopharmaceuticals, Inc: Pharmaceuticals and Healthcare Company Profile & SWOT Report contains in depth information and data about the company and its operations. The profile contains a company overview, business description, SWOT analysis, key facts, information on products and services, details of locations and subsidiaries, plus information on key news events affecting the company.
ICD Research's Omrix Biopharmaceuticals, Inc: Pharmaceuticals and Healthcare Company Profile & SWOT Report is a crucial resource for industry executives and anyone looking to access key information about Omrix Biopharmaceuticals, Inc..
ICD Research's Omrix Biopharmaceuticals, Inc: Pharmaceuticals and Healthcare Company Profile & SWOT Report report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.
Examines and identifies key information and issues about Omrix Biopharmaceuticals, Inc. for business intelligence requirements.
Studies and presents the company's strengths, weaknesses, opportunities (growth potential) and threats (competition). Strategic and operational business information is objectively reported.
The profile also contains information on business operations, company history, major products and services, prospects, key employees, locations and subsidiaries.
Reasons To Buy
Quickly enhance your understanding of Omrix Biopharmaceuticals, Inc. .
Gain insight into the marketplace and a better understanding of internal and external factors which could impact the industry.
Increase business/sales activities by understanding your competitors’ businesses better.
Recognize potential partnerships and suppliers.
Omrix Biopharmaceuticals, Inc. (Omrix) Omrix Biopharmaceuticals, Inc. (Omrix) is a biopharmaceutical company that develops, manufactures and markets biosurgical and passive immunotherapy products. The company is a subsidiary of Johnson & Johnson, now operates as a stand-alone entity reporting through Johnson & Johnson's subsidiary ETHICON, Inc. Omrix develops innovative biological products from human plasma by utilizing its protein purification technology. The company markets its products under various brand names such as Evicel, Quixil, and Evithrom among others. Under the immunotherapies, Omrix produces IVIG Intravenous IG, VIG Vaccinia IG, and HBIG Hepatitis B IG. Omrix operates in Israel, the US, Europe and Central and Latin America. It owns and operates manufacturing and R & D (Research and Development) facilities, located in Tel Aviv, Israel. Omrix Biopharmaceuticals, Inc. is headquartered in Somerville, New Jersey, the US.